Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) Shares Outstanding (Weighted Average) (2017 - 2021)

Cogent Biosciences has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $37.7 million for Q3 2021.

  • Quarterly results put Shares Outstanding (Weighted Average) at $37.7 million for Q3 2021, up 283.14% from a year ago — trailing twelve months through Sep 2021 was $37.7 million (up 283.14% YoY), and the annual figure for FY2020 was $11.1 million, up 45.42%.
  • Shares Outstanding (Weighted Average) for Q3 2021 was $37.7 million at Cogent Biosciences, down from $38.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for COGT hit a ceiling of $29.9 billion in Q3 2018 and a floor of $7.5 million in Q1 2020.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $10.2 million (2018), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 293060.54% in 2018 and later tumbled 99.97% in 2019.
  • Cogent Biosciences' Shares Outstanding (Weighted Average) stood at $10.2 million in 2017, then skyrocketed by 144.27% to $24.9 million in 2018, then tumbled by 69.39% to $7.6 million in 2019, then surged by 45.42% to $11.1 million in 2020, then soared by 240.59% to $37.7 million in 2021.
  • The last three reported values for Shares Outstanding (Weighted Average) were $37.7 million (Q3 2021), $38.4 million (Q2 2021), and $34.9 million (Q1 2021) per Business Quant data.